ATTRACT 2025 – International Call for Rare Cancer Drug Development
ATTRACT 2025 is the second edition of a pioneering international initiative aimed at accelerating drug development for rare cancers through cross-border clinical academic research. Organized by six European anti-cancer charities, this call focuses on Phase II/III clinical trials for rare cancers, addressing the critical funding gap for therapeutic innovation.
Eligibility Criteria
-
Research consortia must have national coordinators from 3 or 4 countries (France, Belgium, Spain, Netherlands).
-
Projects must involve Phase II or Phase III clinical trials focusing on medicinal products for rare cancers, as defined by RARECARE.
-
Patient involvement is required throughout the full project lifecycle.
-
Applications must be submitted through the Fondation ARC Submission System.
Funding Details
-
The call is organized by Anticancer Fund (Belgium), Scientific Foundation of the Spanish Association Against Cancer (Spain), Fondation ARC (France), Kom op tegen Kanker (Belgium), KWF Dutch Cancer Society (the Netherlands), and Rising Tide Foundation for Clinical Cancer Research (Switzerland).
-
Funding decisions will be made in October–November 2025.
Key Deadlines
-
Full Proposal Application Opening: February 2025
-
Full Proposal Deadline: End of April 2025
-
Rebuttal Week: First half of September 2025
-
Funding Decisions: October–November 2025
Further Information
Applicants can find more information and submit proposals through the Fondation ARC Submission System.
For questions, email: [email protected]
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023